Cardiology Research and Practice最新文献

{"title":"Dapagliflozin Augmentation of Sacubitril/Valsartan Therapy in Patients With Heart Failure Following PCI-Treated Acute Myocardial Infarction: A Meta-Analysis of Clinical Efficacy and Safety.","authors":"Tang Tang, Huimin Yu, Yun Zhang, Shuang Li, Mu Guo","doi":"10.1155/crp/1274068","DOIUrl":"10.1155/crp/1274068","url":null,"abstract":"<p><strong>Purpose: </strong>To systematically review the efficacy and safety of dapagliflozin and sacubitril/valsartan (SV) in patients with heart failure (HF) following percutaneous coronary intervention (PCI)-treated acute myocardial infarction (AMI) and to provide evidence for clinical practice.</p><p><strong>Methods: </strong>Seven electronic databases were systematically searched from their inception to July 25, 2024. Following literature screening, data extraction, and risk of bias assessment, 14 randomized controlled trials involving 1310 patients were included. A meta-analysis was subsequently conducted using RevMan 5.4 and Stata 18.</p><p><strong>Results: </strong>Meta-analysis results showed that dapagliflozin combined with SV was superior to the control in improving left ventricular ejection fraction (LVEF) (WMD = 3.79, 95% CI: 2.70∼4.87; <i>p</i> < 0.001) and reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) levels (WMD = -83.49, 95% CI: -129.33∼-37.65; <i>p</i> = 0.0004). This combination also significantly reduced left ventricular end-diastolic diameter (LVEDD) (WMD = -2.27, 95% CI: -3.64∼-0.90; <i>p</i> = 0.001), left ventricular end-systolic diameter (LVESD) (WMD = -3.29, 95% CI: -3.98∼-2.59; <i>p</i> < 0.001), left ventricular remodeling index (LVRI) (WMD = -0.08, 95% CI: -0.10∼-0.06; <i>p</i> < 0.001), and left ventricular mass index (LVMI) (WMD = -8.84, 95% CI: -12.25∼-5.43; <i>p</i> < 0.001), while increasing the 6-min walking distance (6MWD) (WMD = 51.74, 95% CI: 32.33∼71.14; <i>p</i> < 0.001). Compared with SV monotherapy, adding dapagliflozin reduced major adverse cardiovascular event (MACE) incidence (OR = 0.24, 95% CI: 0.15∼0.39; <i>p</i> < 0.001). However, no significant difference in adverse drug events (ADEs) was observed. Subgroup analyses revealed no significant differences in NT-proBNP (WMD = -194.85, 95% CI: -396.53∼6.82; <i>p</i> = 0.06), LVEDD (WMD = -1.50, 95% CI: -3.90∼0.89; <i>p</i> = 0.22), or the incidence of ADE (OR = 1.26, 95% CI: 0.74∼2.14; <i>p</i> = 0.39) when the follow-up duration was short (≤ 12 w). Additionally, significant heterogeneity was observed across studies for most outcomes. However, this heterogeneity was markedly reduced in the long-term follow-up subgroup (≥ 24 w), and the results were consistent with those of previous meta-analyses.</p><p><strong>Conclusion: </strong>Current evidence suggests that early initiation of dapagliflozin combined with SV offers superior efficacy and cardiovascular benefits for patients with HF following PCI-treated AMI. These benefits become increasingly evident with sustained treatment. Nevertheless, these conclusions warrant validation through more high-quality evidence.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"1274068"},"PeriodicalIF":2.1,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13376590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148577003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ionic Disorders in Persistent Atrial Fibrillation: Therapeutic Targeting by Plant-Derived Bioactive Compounds.","authors":"Yize Zhai, Na Shi, Wenzhuo Duan, Jianfei Yang","doi":"10.1155/crp/2123244","DOIUrl":"10.1155/crp/2123244","url":null,"abstract":"<p><p>Persistent atrial fibrillation (AF) is associated with distinct ion channel abnormalities and their regulatory mechanisms. This review explores the potential of plant-derived bioactive compounds to correct these dysfunctions. As a prevalent cardiac arrhythmia, AF involves a complex pathogenesis featuring dysregulated activity in potassium, sodium, and calcium channels. Such ionic disturbances foster electrophysiological instability in cardiomyocytes, which contributes to AF initiation and sustenance. Plant-based compounds have attracted considerable attention for their multitargeted actions, low toxicity, and biocompatibility. Emerging evidence indicates that specific phytochemicals can modulate ion channel function and improve myocardial electrical stability, offering potential avenues for AF therapy. However, the precise mechanisms and clinical translational potential of these compounds require further elucidation. By systematically synthesizing current knowledge, this review assesses the value of plant-derived compounds in rectifying ionic imbalances, with the aim of informing the development of novel antiarrhythmic therapies and future research directions.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"2123244"},"PeriodicalIF":2.1,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13349995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Network Pharmacology Analysis and Experimental Validation of Zadi-5 Against Coronary Heart Disease.","authors":"Jie Xiang, Jing Liu, Pengmei Liu","doi":"10.1155/crp/5479556","DOIUrl":"10.1155/crp/5479556","url":null,"abstract":"<p><p>This study aimed to investigate the potential molecular mechanisms underlying the therapeutic effects of the traditional Mongolian medicine Zadi-5 on coronary heart disease (CHD). The active compounds of Zadi-5 were identified using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, and their corresponding targets were retrieved from HERB. The GSE42148 dataset was used to analyze differentially expressed genes (DEGs) associated with CHD. A compound-target network and a disease-gene-target network were constructed, followed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. Molecular docking was performed to predict binding modes. Furthermore, we employed a CHD model with high-fat diet-fed ApoE^-/- mice to explore the protective effects of Zadi-5 in CHD. A total of 250 targets related to the active compounds in Zadi-5 were identified. Additionally, 480 DEGs were screened from the GSE42148 dataset, and seven key targets (MPO, IFNG, TOP2A, PTGS2, CYP2J2, F7, and PPARG) were identified. Molecular docking predicted strong binding affinities between PPARG and the main active components of Zadi-5. Furthermore, Zadi-5 markedly enhanced the heart performance and reduced fibrotic and inflammatory responses in vivo. Zadi-5 effectively suppressed the levels of HIF-1α and increased the PPARG levels in ApoE^-/- mice post-myocardial infarction. These findings suggest that the active components of Zadi-5 may exert therapeutic effects in CHD by targeting PPARG, as revealed by network pharmacology and molecular docking analyses.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"5479556"},"PeriodicalIF":2.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148403667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Aortic Dilation in Patients With Hypertrophic Cardiomyopathy in a Tertiary Center for Cardiovascular Disease.","authors":"Tahereh Babaei, Kosar Babaei, Golnaz Houshmand, Farzaneh Amini, Parham Rabiee, Zeinab Norouzi, Hamideh Khesali, Raheleh Kaviani","doi":"10.1155/crp/7137001","DOIUrl":"10.1155/crp/7137001","url":null,"abstract":"<p><strong>Background: </strong>Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disease primarily affecting the left ventricle. While the disease is traditionally associated with myocardial hypertrophy and left ventricular outflow tract (LVOT) obstruction, aortic dilation has emerged as a potentially serious but underrecognized complication. This study aimed to determine the prevalence of aortic dilation in HCM patients and to identify associated clinical and echocardiographic factors.</p><p><strong>Methods: </strong>In this cross-sectional, retrospective study, 216 adult patients diagnosed with HCM at Rajaie Cardiovascular Institute (Tehran, Iran) from 2016 to 2021 were evaluated. Patients with significant valvular disease, congenital aortic anomalies, prior aortic surgery, or other cardiomyopathies were excluded. Clinical data and echocardiographic measurements, including aortic dimensions indexed to body surface area (BSA), were collected. Cardiac magnetic resonance imaging (MRI) data of myocardial fibrosis were also assessed in a subset of patients. Logistic regression was used to identify factors independently associated with aortic dilation.</p><p><strong>Results: </strong>Dilated ascending aorta was present in 56 patients (26.3%), while 12 patients (5.6%) had dilation of the sinus of Valsalva (SOV). Dilated ascending aorta was significantly associated with older age (<i>p</i> = 0.001), hypertension (<i>p</i> = 0.001), and increased BSA (<i>p</i> = 0.002). LV end-systolic diameter (LVESD) also showed a significant correlation (<i>p</i> = 0.002). Multivariate analysis identified age (OR = 1.063), hypertension (OR = 5.49), LVESD (OR = 3.25), and right ventricular hypertrophy (OR = 4.99) as independent predictors of ascending aorta dilation. SOV dilation was similarly associated with age (OR = 1.117) and lower weight (OR = 0.915). Although myocardial fibrosis was more common in patients with ascending aorta dilation, this did not reach statistical significance (<i>p</i> = 0.006).</p><p><strong>Conclusion: </strong>Aortic dilation is a relatively common finding in patients with HCM and is significantly associated with age, hypertension, and structural cardiac remodeling. Routine evaluation of the ascending aorta and SOV in HCM patients may aid in the early detection and management of this potential complication.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"7137001"},"PeriodicalIF":2.1,"publicationDate":"2026-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13333929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148435108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging Role of Statin Therapy in Preventing Anthracycline-Induced Cardiotoxicity.","authors":"Elissar Mansour, Nawal Abi Raji, Pia Salloum, Nicolas Jreij, Thea Mila Ayoub, Mostafa Merheb, Philippe Attieh, Bernard Harbieh, Frederic Harb, Sami Azar, Hilda E Ghadieh","doi":"10.1155/crp/9734869","DOIUrl":"10.1155/crp/9734869","url":null,"abstract":"<p><p>Several randomized controlled trials (RCTs), animal studies, and observational studies have demonstrated the cardioprotective effects of statins, though their effectiveness varies. The observed variability may be attributed to individual differences, patient ages, disparities in statin type and dosage of anthracyclines (ANT) administered, and variations in cancer conditions among patients. Overall, statins play a beneficial role in reducing oxidative stress and inflammation, enhancing tumor sensitivity to chemotherapeutic drugs, improving mitochondrial function in cardiac cells, exerting antiapoptotic effects, and preserving left ventricular ejection fraction (LVEF). Despite these promising findings, the long-term effects of statins remain unclear due to the lack of a standardized protocol. Statins may also cause side effects by depleting essential substances in the body. This limitation underscores the need for further research to assess their long-term impact and establish standardized guidelines for dosing, duration, and potential side effects. The implications of this review highlight the importance of understanding the pleiotropic effects of statins to develop targeted therapies for chemotherapy-induced cardiotoxicity. Additionally, integrating ongoing research into clinical guidelines is essential, ensuring that clinicians carefully consider patient-specific factors when prescribing statins alongside ANT. This present review explores the potential role of statins in mitigating ANT-induced cardiotoxicity, a major complication of chemotherapy that reduces LVEF and leads to heart failure (HF).</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"9734869"},"PeriodicalIF":2.1,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13312984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148350794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applicability of Stress Cardiac Magnetic Resonance Imaging in Patients With Cardiac Implantable Devices: A Systematic Review.","authors":"Sarina Zakavi, Mohammad Rafie Khorgami, Pedram Babaee, Alireza Babaeizadeh, Rahem Rahmati, Mina Felfeli, Elahe Meftah, Golnaz Houshmand, Fatemeh Abedpour, Amirfarjam Fazelifar, Hamidreza Pouraliakbar, Hamidreza Hekmat, Negar Omidi","doi":"10.1155/crp/3131535","DOIUrl":"10.1155/crp/3131535","url":null,"abstract":"<p><strong>Purpose: </strong>The utilization of stress perfusion cardiac magnetic resonance (CMR) in patients with cardiac implantable electronic devices (CIEDs) is still limited.</p><p><strong>Methods: </strong>The study was registered in the Prospective Register of Systematic Reviews (PROSPERO) with ID CRD42023457308. PubMed, Scopus, Embase, Web of Science, ProQuest, and CINAHL databases were searched using the Mesh and related terms of CMR imaging, stress, and CIEDs.</p><p><strong>Results: </strong>Out of the 1695 papers we found, eight met our inclusion criteria. We reviewed the included studies and provided a concluding remark concerning (a) image quality; (b) CMR compatibility, scanner, and safety; (c) device protocols and exclusion criteria; (d) vasodilator choices, effects, and safety; and (e) clinical outcomes.</p><p><strong>Conclusion: </strong>This study has demonstrated a positive trend in the utilization of stress CMR in MR-conditional devices. However, the review has identified multiple research gaps that warrant further investigation.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"3131535"},"PeriodicalIF":2.1,"publicationDate":"2026-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13310391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148343986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotypic Age Acceleration as a Mediator in Thyroid Hormone-Related Cardiovascular Risk Among the Elderly.","authors":"Minmin Wen, Yanjun Hou, Kaijia Shi, Jiaxin Zuo, Cheng Zhang, Shuya Zhang, Zhihua Shen, Wei Jie","doi":"10.1155/crp/1206757","DOIUrl":"10.1155/crp/1206757","url":null,"abstract":"<p><strong>Background: </strong>The association between thyroid hormones and cardiovascular disease (CVD) has been widely examined; however, the role of biological aging in this relationship remains unclear. This study systematically investigates the mediating role of phenotypic age acceleration (PhenoAgeAccel) in the relationship between thyroid hormones and CVD.</p><p><strong>Methods: </strong>The data were sourced from the 2007-2010 cycles of the National Health and Nutrition Examination Survey (NHANES). Analyses included logistic regression, linear regression, restricted cubic splines, subgroup analyses, and mediation analysis to assess the role of PhenoAgeAccel.</p><p><strong>Results: </strong>Among participants aged ≥ 60 years, elevated free triiodothyronine (FT3) concentrations were linked to a reduced risk of CVD (adjusted odds ratio [aOR] = 0.483; 95% CI: 0.273-0.856; <i>p</i> = 0.013). Similarly, total triiodothyronine (TT3) levels were associated with a decreased CVD risk in those aged 60 and above (aOR = 0.988; 95% CI: 0.980-0.995; <i>p</i> = 0.013). Mediation analysis showed that PhenoAgeAccel mediated 21.13% of the FT3-CVD association and 23.41% of the TT3-CVD association in older adults.</p><p><strong>Conclusion: </strong>This study identifies an age-dependent relationship between FT3, TT3, and CVD and reveals that PhenoAgeAccel partially mediates this association. These findings suggest that interventions targeting thyroid function and biological aging may offer novel strategies for CVD prevention and management in older populations.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"1206757"},"PeriodicalIF":2.1,"publicationDate":"2026-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13311311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148350807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Equation for Peak Heart Rate and First Ventilatory Threshold Heart Rate in Patients With Coronary Heart Disease.","authors":"Xianghui Zheng, Peiyao Wang, Shiyu Wang, Haoning Cui, Hu Tan, Lida Guan, Shujiang Zhang, Hongyan Zhang, Fang Wang, Xinyu Hou, Qifeng Li, Tianhui Cao, Yang Zheng, Xiaojun Wu, Jian Wu, Bo Yu","doi":"10.1155/crp/4446755","DOIUrl":"10.1155/crp/4446755","url":null,"abstract":"<p><strong>Background: </strong>Peak heart rate (HR peak) and first ventilatory threshold heart rate (HR VT1) guide exercise prescription formulation, but existing formulas lack accuracy in coronary heart disease (CHD) patients due to unaccounted pathophysiological differences. This study aimed to construct prediction equation for HR peak and HR VT1 in CHD patients.</p><p><strong>Methods: </strong>This was a multicenter retrospective study that included 14,465 cases of cardiopulmonary exercise test (CPET) data from CHD patients in 20 hospitals in China. Seventy percent of the cohort was divided into a development group (<i>n</i> = 10,125), and the remaining 30% served as a validation group (<i>n</i> = 4340). Stepwise multiple backward regression established HR peak and HR VT1 equations, with accuracy compared to traditional formulas.</p><p><strong>Results: </strong>Age, weight, resting heart rate (HR rest), CHD diagnostic category, and β-blockers were included in the equation. The mean absolute percentage error (MAPE) of China-CPET-HR peak is 9.04%, with an adjusted coefficient of determination (<i>R</i> ²) of 0.399. For the China-CPET-HR VT1 formula, the MAPE is 7.32% and the adjusted <i>R</i> ² is 0.509. The %HR peaks of the FOX, TANAKA, KETEYIAN, and China-CPET-HR peak formulas are 82 ± 11%, 79 ± 11%, 105 ± 13%, and 100 ± 11%, respectively.</p><p><strong>Conclusion: </strong>Based on CPET data from CHD patients, we developed prediction equations for HR peak and HR VT1. The prediction accuracy of these equations is significantly higher than others, which helps to formulate accurate individualized exercise prescriptions and rehabilitation training guidance for CHD patients.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"4446755"},"PeriodicalIF":2.1,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13288608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148315890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electroacupuncture Protects Against Post-MI Heart Failure Through Autonomic Regulation and α7nAChR Activation.","authors":"Weiting Wang, Jiaojiao Wu, Yueling Xu, Qiao Lin, Ke Wang, Aijun Liu, Jia Zhou","doi":"10.1155/crp/9919619","DOIUrl":"10.1155/crp/9919619","url":null,"abstract":"<p><strong>Objective: </strong>This study investigated whether electroacupuncture (EA) at Neiguan (PC6) acupoint alleviates adverse myocardial remodeling in post-myocardial infarction (MI) heart failure (HF) by activating the vagus nerve-mediated cholinergic pathway and its downstream α7nAChR-Akt-HIF-1α-VEGF signaling cascade.</p><p><strong>Methods: </strong>Male Sprague Dawley (SD) rats were randomized into sham, MI model, and EA groups (<i>n</i> = 6 per group). MI was induced by ligation of the left anterior descending coronary artery. EA was applied at PC6 for 14 days starting 1 week after MI induction. Cardiac function and structure were evaluated using echocardiography and histological examination. The expression levels of choline acetyltransferase (ChAT), α7-nicotinic acetylcholine receptor (α7nAChR), phosphorylated Akt (<i>p</i>-Akt), hypoxia-inducible factor-1α (HIF-1α), and vascular endothelial growth factor (VEGF) were analyzed by real-time quantitative PCR, Western blotting, and immunohistochemistry.</p><p><strong>Results: </strong>EA intervention significantly attenuated pathological myocardial remodeling and improved cardiac function. Compared with the model group, EA treatment markedly enhanced cardiac function, increased contractility, reduced ventricular dilation, restored autonomic balance, and alleviated myocardial necrosis and fibrosis. Molecular studies revealed that EA treatment increased the expression of ChAT and α7nAChR, elevated <i>p</i>-Akt levels, and upregulated the expression of HIF-1α and VEGF. These findings suggest the activation of the vagus nerve-cholinergic signaling pathway and its downstream prosurvival and pro-angiogenic pathways.</p><p><strong>Conclusions: </strong>EA attenuated maladaptive ventricular remodeling and improved cardiac performance. These effects were associated with modulation of autonomic function and engagement of the α7nAChR/Akt/HIF-1α/VEGF signaling axis, supporting a potential neuro-immune-angiogenic mechanism underlying EA-mediated myocardial repair during the subacute post-MI phase.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"9919619"},"PeriodicalIF":2.1,"publicationDate":"2026-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13287330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148315868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of Controlling Nutritional Status Score and Systemic Immune-Inflammation Index With Frailty and Prognosis in Chronic Heart Failure Patients With Atrial Fibrillation.","authors":"Jun Wang, Jun Wu Xing, Guang Gan Bo","doi":"10.1155/crp/5244972","DOIUrl":"10.1155/crp/5244972","url":null,"abstract":"<p><strong>Objective: </strong>To explore the predictive value of the controlling nutritional status (CONUT) score combined with the systemic immune-inflammation index (SII) for frailty and prognosis in chronic heart failure (CHF) patients with atrial fibrillation (AF).</p><p><strong>Methods: </strong>This retrospective study included 264 patients with CHF and AF who were admitted to and treated at the inpatient and outpatient departments of Nanjing Integrated Traditional Chinese and Western Medicine Hospital from January 2016 to July 2019. Follow-up ended upon patient death, with the final follow-up deadline set for September 2024. Binary logistic regression and Cox regression were used to identify factors influencing frailty and all-cause mortality. The cutoff values for the CONUT score and SII are determined by the ROC diagnostic threshold for mortality. Cutoff values for the CONUT score and SII were 6.5 and 990.2, respectively, categorizing patients into four groups: G1 (high CONUT ≥ 6.5 and high SII ≥ 990.2), G2 (high CONUT ≥ 6.5 and low SII < 990.2), G3 (low CONUT < 6.5 and high SII ≥ 990.2), and G4 (low CONUT < 6.5 and low SII < 990.2).</p><p><strong>Results: </strong>Frailty was present in 165 patients (165/264). Multivariate logistic regression identified disease duration, CONUT score, and SII as significant factors for frailty. A positive correlation between CONUT and SII was observed (<i>r</i> = 0.648, <i>p</i> < 0.001). Cox regression analysis found smoking, CONUT, and SII as risk factors for mortality. Survival analysis showed lower survival rates in high CONUT and high SII groups (<i>p</i> < 0.001), with the G1 group having the lowest survival rate compared to G2, G3, and G4 (<i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>The CONUT score and SII are useful predictors of frailty and mortality in CHF patients with AF. Their combined use may improve the assessment of frailty and prognosis in this population.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"5244972"},"PeriodicalIF":2.1,"publicationDate":"2026-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13284492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}